MARKET

ISEE

ISEE

IVERIC bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.33
+0.41
+8.33%
Pre Market: 5.45 +0.12 +2.25% 08:46 09/28 EDT
OPEN
4.890
PREV CLOSE
4.920
HIGH
5.38
LOW
4.870
VOLUME
60
TURNOVER
--
52 WEEK HIGH
8.97
52 WEEK LOW
0.9059
MARKET CAP
477.05M
P/E (TTM)
-3.9578
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
IVERIC bio, Inc. (ISEE): Hedge Funds Are Snapping Up
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually
Insider Monkey · 09/15 06:02
IVERIC bio to Participate in Upcoming September Investor / Industry Conferences
IVERIC bio announced that the Company will participate in the two upcoming virtual investor conferences and a retina showcase conference in September.
Business Wire · 09/03 12:00
IVERIC Bio Highlights Publication Of GATHER1 Phase 3 Clinical Trial Results For Zimura In Geographic Atrophy Secondary To Age-Related Macular Degeneration, In Ophthalmology, The Journal Of The American Academy Of Ophthalmology
IVERIC bio, Inc. (NASDAQ:ISEE) today announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the
Benzinga · 09/01 12:46
IVERIC bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology
IVERIC announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® were published in Ophthalmology®.
Business Wire · 09/01 12:45
IVERIC Bio shares are trading higher after Credit Suisse initiated coverage on the stock with an Outperform rating and a price target of $13 per share.
Benzinga · 08/13 12:31
Credit Suisse Initiates Coverage On IVERIC bio with Outperform Rating, Announces Price Target of $13
Credit Suisse initiates coverage on IVERIC bio (NASDAQ:ISEE) with a Outperform rating and announces Price Target of $13.
Benzinga · 08/13 10:02
IVERIC bio, Inc. 2020 Q2 - Results - Earnings Call Presentation
Seeking Alpha - Article · 08/09 10:30
IVERIC bio, Inc. 2020 Q2 - Results - Earnings Call Presentation
The following slide deck was published by IVERIC bio, Inc. in conjunction with their 2020 Q2 earnings call.
Seekingalpha · 08/09 10:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ISEE. Analyze the recent business situations of IVERIC bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ISEE stock price target is 13.00 with a high estimate of 15.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 160
Institutional Holdings: 82.93M
% Owned: 92.66%
Shares Outstanding: 89.50M
TypeInstitutionsShares
Increased
34
17.20M
New
66
30.03M
Decreased
19
3.42M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Executive Director
David Guyer
President/Chief Executive Officer/Director
Glenn Sblendorio
Chief Financial Officer/Senior Vice President/Treasurer
David Carroll
Chief Operating Officer/Senior Vice President
Keith Westby
Chief Scientific Officer
Abraham Scaria
Lead Director/Independent Director
Adrienne Graves
Director
Mark Blumenkranz
Independent Director
Axel Bolte
Independent Director
Jane Henderson
Independent Director
Calvin Roberts
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ISEE
IVERIC bio, Inc., formerly Ophthotech Corporation, is a biopharmaceutical company. The Company is focused on the discovering and developing of novel gene therapy solutions to treat orphan inherited retinal diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. The Company’s BEST1 gene encodes a multifunctional protein known as bestrophin1, that regulates ion transport and intracellular calcium signaling in retina cells and helps maintain homeostasis in the sub retinal space between photoreceptors and the retinal pigment epithelial (RPE) cells. Its IC-200 is a mutation independent gene therapy, delivered by an AAV2 vector.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of IVERIC bio Inc stock information, including NASDAQ:ISEE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISEE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISEE stock methods without spending real money on the virtual paper trading platform.